About Apracap Aprepitant Capsules
| Brand |
Aprecap |
| Usage/Application |
Hospital |
| Packaging Type |
Box |
| Strength |
125, 80 mg |
| Manufactured By |
Glenmark Pharmaceuticals Ltd |
| Medicine Type |
Allopathic |
| Form |
Capsules |
Aprecap 125/80
Capsule is a prescription medicine used in the treatment of nausea or vomiting experienced as a side effect of chemotherapy or anti-cancer treatment. It inhibits the signal to reach the brain that causes the feeling of nausea or vomiting.
Advanced Nausea Relief for Chemotherapy PatientsApracap Capsules utilize aprepitant, an NK1 receptor antagonist, to effectively reduce the occurrence of nausea and vomiting caused by chemotherapy. Co-administered with other antiemetic agents, Apracap targets a key pathway responsible for triggering these symptoms, thereby enhancing patient comfort and supporting the continuation of cancer treatment regimens.
Easy Oral Dosing, Secure PackagingDesigned for convenient oral administration, Apracap comes in solid capsule form with dosages typically directed by the physician. Each blister pack ensures product integrity and extends shelf life, safeguarding the medicine from moisture, light, and contamination until use.
Quality Assurance and International AvailabilityManufactured in India by Intas Pharmaceuticals Ltd., Apracap is distributed globally and meets stringent export quality standards. With a shelf life of two years, this medicine is readily available in hospital and pharmacy supply chains, fulfilling clinical and logistical needs worldwide.
FAQ's of Apracap Aprepitant Capsules:
Q: How should Apracap Aprepitant Capsules be taken?
A: Apracap capsules should be swallowed whole with water, following the specific dosage and schedule advised by your physician. They are usually taken once daily as part of a combined antiemetic regimen for patients undergoing chemotherapy.
Q: What are the benefits of using Apracap during chemotherapy?
A: Apracap helps prevent nausea and vomiting associated with chemotherapy, allowing patients to better tolerate treatment and potentially improving their overall comfort and treatment adherence.
Q: When is Apracap typically administered to patients?
A: Apracap is generally initiated just prior to the start of chemotherapy, as directed by the prescribing physician, and is continued for a short duration based on the chemotherapy schedule and patient needs.
Q: Where can I obtain Apracap Capsules?
A: Apracap is supplied through hospital and pharmacy distribution channels and is available internationally. It requires a prescription and is dispensed by licensed healthcare providers or pharmacies.
Q: What strength options are available for Apracap Aprepitant Capsules?
A: The capsules are available in two strengths-80 mg and 125 mg-depending on the prescribed regimen. The dosage and strength selection will be determined by your healthcare provider.
Q: What is the proper way to store Apracap Capsules?
A: Store Apracap capsules in a cool, dry environment below 25C, protected from light, and ensure they remain within their original packaging until use to maintain efficacy and safety.
Q: Who is suitable for Apracap treatment?
A: Apracap is recommended for adults undergoing chemotherapy, as prescribed by a healthcare professional. It is not indicated for pediatric use or for conditions other than chemotherapy-induced nausea and vomiting.